All News
3-4-5 Rule (5.26.2023)
Dr. Jack Cush reviews more than a dozen news, journal articles and RNL highlights from this past week on RheumNow.com.
Read Article
Prevalence of Psoriatic Arthritis, Spondyloarthritis and Rheumatoid Arthritis in Norway
Recent reports have suggested a rising and unrecognized number of patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) compared to rheumatoid arthritis (RA).
Read Article
Dr. Deodhar reminds us of his "3,4,5 rule" for diagnosing AS.
*Erosions in 3 or more SIJ quadrants
*BME in 4 or more SIJ quadrants
*Fat lesions in 5 of more SIJ quadrants
#RNL2023 @RheumNow https://t.co/T9iWLcNL8b https://t.co/BskCNz9Klj
Links:
Dr. John Cush RheumNow ( View Tweet)
Peresolimab's Potential in Rheumatoid Arthritis
Peresolimab is a humanized IgG1 monoclonal antibody that acts as a PD-1 agonist (stimulator). The NEJM reports that PER met its efficacy primary endpont in treating patients with active RA.
https://t.co/tBAC2vO31f https://t.co/pAknsSnnNT
Links:
Dr. John Cush RheumNow ( View Tweet)
U.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults based on induction studies, U-EXCEED, U-EXCEL,& U-ENDURE maintenance study. This is 7th FDA approval for RINVOQ https://t.co/JFyiETe43S https://t.co/zGJKZ3l0d4
Links:
Dr. John Cush RheumNow ( View Tweet)
Join us for the final Tuesday Night Rheumatology of May.
This webinar will feature highlights from these lectures followed by live audience Q & A:
Methotrexate Use: 50 Yr. Perspective
Myths vs Reality in RA
Biosimilars - Back on the Agenda
https://t.co/cqFNCRlGym https://t.co/fNS6cGBuDB
Links:
Dr. John Cush RheumNow ( View Tweet)
Save the date! We'll be tuning in live from Milan for EULAR '23. Count on us for:
-KOL perspective videos
-Clinical Trial Highlights
-Daily Faculty Recaps
-Live Streaming
and more! https://t.co/uR4ZwnPGiF
Dr. John Cush RheumNow ( View Tweet)
Ph 3 study 800 ICU pts w/ severe community acq pneumonia shows those on IV hydrocortisone had lower mortality at day 28 (6.2% vs 11.9%; P=0.006), less intubation (18% vs 29.5%), less vasopressors (15% v 25%) vs PBO; no Diff w/ infx rates or GI bleed https://t.co/BjIM8UJXZS https://t.co/389CZovrZm
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch our video presented by leading expert Dr. Michelle Petri to learn why complete renal response matters in #LupusNephritis. #SponsoredbyGSKUSMA
https://t.co/XFZH5HprH4 https://t.co/PYfHy6uoZt
Links:
Dr. John Cush RheumNow ( View Tweet)
AxSpA is primarily a genetic disease
- clusters in families, especially HLA-B27+ first degree relatives
- genetic testing for asymptomatic relatives not recommended
@RheumNow #RNL2023 https://t.co/WeNApLE5to https://t.co/zDzHfdmpCG
Links:
Dr. John Cush RheumNow ( View Tweet)
⚠️Beware not all bone marrow oedema =#AxSpA on MRI !
Signal seen in 17% volunteers at SIJs
@DrPoddubnyy
#RNL2023 https://t.co/c4gqnBzdnO https://t.co/kZiX8r62aY
Links:
Dr. John Cush RheumNow ( View Tweet)
Risk of familial AS is 19.4%, Reveille #RNL2023 @RheumNow https://t.co/7CzaXgqkPG https://t.co/KrmKGblVmd
Links:
Dr. John Cush RheumNow ( View Tweet)
"50 years ago in April we discovered HLA B27." Dr. Reveille #RNL2023 @RheumNow
Dr. John Cush RheumNow ( View Tweet)
Bone marrow edema was found in healthy individuals, Denis Poddubnyy #RNL2023 @RheumNow https://t.co/1n6E2QuGut https://t.co/y9Zzw6rdqN
Links:
Dr. John Cush RheumNow ( View Tweet)
What to look for( MRI ), Denis Poddubnyy #RNL2023 @RheumNow
STIR: inflammation
T1 erosion, fatty changes
VIBE: erosion https://t.co/enHned1acr
Links:
Dr. John Cush RheumNow ( View Tweet)
FRAX Tool is Suboptimal in Predicting Osteoporosis Fracture Risk in Younger Post-menopausal Women
https://t.co/oNTKZXSrzn https://t.co/OlbCuSuLlo
Links:
Dr. John Cush RheumNow ( View Tweet)
In the UK, MHRA has somewhat softened its warnings on Febuxostat use in gout - stating use caution if considering Febuxostat in patients with a prior history of major cardiovascular disease; esp w/ high urate and tophi burden or starting ULT https://t.co/y0KhXtgzzG https://t.co/5ZlE0XK8qx
Links:
Dr. John Cush RheumNow ( View Tweet)
The Burden of Chronic Pain in US Adults (2019-2020)
Analysis of National Health Interview Survey data shows that the incidence of chronic pain in the USA is high compared with other chronic diseases.
https://t.co/mH6Zb3i3Vw https://t.co/PWI8R6mKJR
Links:
Dr. John Cush RheumNow ( View Tweet)
J&J lawsuit against Amgen (Nov 2022) over Amgens biosimilar of Stelara has been settled (terms undisclosed) such that the Amgen biosimilar cannot be US marketed until 1/1/2025. Stelaras 2022 revenue was $9.7 billion https://t.co/NVgBsBNxk1 https://t.co/Fj8rn05RW0
Links:
Dr. John Cush RheumNow ( View Tweet)
Women’s health research lacks funding – these charts show how -- Nature has published a very slick/graphical representation of the deficient research funding (US NIH & UK UK Medical Research Council) of diseases affecting women. https://t.co/hJ8DzKxHeW https://t.co/aHoQTKOlRF
Dr. John Cush RheumNow ( View Tweet)
